A Single-center, Randomized, Double-blind, Single and Multiple Dosing, Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
Latest Information Update: 08 Jul 2024
At a glance
- Drugs HEC 121120 (Primary) ; Entecavir
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Sunshine Lake Pharma
- 24 Jun 2024 Status changed from suspended to discontinued. (Company decision to discontinue trial )
- 10 Apr 2023 Planned End Date changed from 12 Mar 2023 to 30 Dec 2023.
- 10 Apr 2023 Planned primary completion date changed from 7 Jul 2022 to 30 Dec 2023.